Literature DB >> 14632855

The subjective and objective benefits of a remote-controlled intraurethral device for managing the female acontractile bladder.

W J Lynch1, G A Testa, D F Bell.   

Abstract

OBJECTIVE: To determine the subjective and objective benefits of the Inflow (SRS Medical Systems, N. Billerica, MA, USA) intraurethral device for managing acontractile bladders in women. PATIENTS AND METHODS: Twenty women with acontractile bladders who had been managed unsuccessfully by the usual methods were recruited. All patients were asked to complete a quality-of-life (QoL) questionnaire and were assessed with urine flowmetry and urine culture; to measure the postvoid residual urine (PVR) in the bladder, ultrasonography was used after activating the device.
RESULTS: There was a decrease in the QoL score from a mean of 59.6 before insertion to means of 11.2, 8.8, 6.3 and 5.0 at 1, 3, 6 and 12 months afterward. The mean (range) urinary flow rate was 10.7 (9-16) mL/s and the PVR 3 (0-17) mL. Three patients had temporary asymptomatic bacteriuria and two a single infection after the device was inserted that settled readily with antibiotics.
CONCLUSION: This study shows that the Inflow device provides an effective method of bladder drainage, with few side-effects and a significant improvement in QoL.

Entities:  

Mesh:

Year:  2003        PMID: 14632855     DOI: 10.1111/j.1464-410x.2003.04525.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  2 in total

1.  Low-frequency electrotherapy for female patients with detrusor underactivity due to neuromuscular deficiency.

Authors:  Dan-Feng Xu; Shen Zhang; Cun-Zhou Wang; Jun Li; Chuang-Yu Qu; Xin-Gang Cui; Sheng-Jia Zhao
Journal:  Int Urogynecol J       Date:  2012-03-23       Impact factor: 2.894

2.  The inFlow intraurethral valve-pump for women with detrusor underactivity: A summary of peer-reviewed literature.

Authors:  Siobhan M Hartigan; Roger R Dmochowski
Journal:  J Spinal Cord Med       Date:  2020-10-15       Impact factor: 2.040

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.